Evidence map›Paper›PMID 42140903›Full record

ArticleNature communications2026

Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge.

Mart van Rijthoven, Witali Aswolinskiy, Leslie Tessier, Roberto Salgado, Jeroen van der Laak, Francesco Ciompi, TIGER consortium

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. QuRad: Radiomics Feature Extraction for QuPath.Computational and structural biotechnology journal · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mart van Rijthoven *Radboud University Medical Center, Nijmegen, The Netherlands.
Witali Aswolinskiy *Radboud University Medical Center, Nijmegen, The Netherlands.
Leslie Tessier *Radboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-9046-9862
Roberto SalgadoDivision of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-1110-3801
Jeroen van der LaakRadboud University Medical Center, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0001-7982-0754
Francesco CiompiRadboud University Medical Center, Nijmegen, The Netherlands. francesco.ciompi@radboudumc.nl.ORCID http://orcid.org/0000-0001-8327-9606
TIGER consortium

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 825292Innovative Medicines Initiative (IMI) 945358KWF Kankerbestrijding (Dutch Cancer Society) 11917
6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) is a recognized prognostic biomarker in breast cancer. However, poor interobserver agreement and limited reproducibility highlight the need for computational approaches. Despite advances, adoption of computational models has been hindered by lack of standardized methods and robust benchmarks. To address this, we launched TIGER, an international competition to build open-source computational TILs (cTILs) models. Here, we present a multi-centric analysis of cTILs methods on resections and biopsies from 3,708 human epidermal growth factor receptor 2-positive (HER2+) or triple-negative breast cancers (TNBC) from clinical practice and phase 3 trials. We report benchmarks on image analysis performance, show strong agreement of cTILs with pathologists, and demonstrate positive association of cTILs with neoadjuvant therapy response in HER2+, superior to visually scored TILs. We also show that cTILs add independent prognostic information to clinical variables in TNBC resections. Data, methods and benchmarks are publicly available: https://tiger.grand-challenge.org/ .

Indexed as

Breast NeoplasmsLymphocytes, Tumor-InfiltratingTriple Negative Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansNeoadjuvant TherapyPrognosisERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID42140903
PMCPMC13377072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.